Wakisaka Masarori, Nagao Tetsuhiko
Wakisaka Naika (Wakisaka Internal Medicine Clinic), Fujisaki 1-24-19, Fukuoka, 814-0013, Japan.
Midori no Clinic (Midori Internal Medicine Clinic), Aoba 7-26-1, Fukuoka 813-0025, Japan.
Glycobiology. 2017 Aug 1;27(8):691-695. doi: 10.1093/glycob/cwx047.
Retinopathy and nephropathy are life-threatening diabetic complications that decrease patient quality of life. Although the mechanisms underlying these conditions have been extensively studied, they remain unknown. Recent reports have demonstrated the presence of sodium glucose cotransporter 2 (SGLT2) in retinal pericytes and mesangial cells. Hyperglycemia results in functional and morphological changes in these cells, but these effects are attenuated by phlorizin, a nonselective SGLT inhibitor. Based on these findings, we hypothesized that SGLT2 plays a pivotal role in the development of diabetic nephropathy and retinopathy and that SGLT2 inhibitors may directly protect against these complications.
视网膜病变和肾病是危及生命的糖尿病并发症，会降低患者的生活质量。尽管对这些病症的潜在机制已进行了广泛研究，但仍不清楚。最近的报告表明，视网膜周细胞和系膜细胞中存在钠葡萄糖协同转运蛋白2（SGLT2）。高血糖会导致这些细胞发生功能和形态变化，但这些作用会被非选择性SGLT抑制剂根皮苷减弱。基于这些发现，我们推测SGLT2在糖尿病肾病和视网膜病变的发展中起关键作用，并且SGLT2抑制剂可能直接预防这些并发症。
